Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Autoimmune Disorders

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correction: PIGN spatiotemporally regulates the spindle assembly checkpoint proteins in leukemia transformation and progression.

Scientific reports·2026

Same author

Noninvasive Monitoring of Complement Using the Bioluminescent Modified Ham Assay in the Second Porcine-to-Human Live Heart Transplant.

Xenotransplantation·2026

Same author

Defining "Dominance" in Atypical Hemolytic Uremic Syndrome: Distinguishing Amplification From Initiation.

Kidney international reports·2026

Same author

Real-World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry.

American journal of hematology·2026

Same author

Ravulizumab for treatment of paroxysmal nocturnal hemoglobinuria during pregnancy.

Blood advances·2026

Same author

Bone marrow transplantation for sickle cell disease using posttransplantation cyclophosphamide and 400 cGy TBI.

Blood advances·2026

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

High-dose cyclophosphamide for autoimmunity and alloimmunity.

Robert A Brodsky¹

¹The Division of Hematology, Johns Hopkins University School of Medicine, Ross Research Building, Baltimore, MD 21205, USA. brodsro@jhmi.edu

Immunologic Research

|January 21, 2010

Summary

High-dose cyclophosphamide (high-CY) effectively treats autoimmune and alloimmune diseases. Its targeted action spares stem cells, making it immunosuppressive without being myeloablative.

More Related Videos

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Related Experiment Videos

Last Updated: Jun 16, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Area of Science:

Immunology
Hematology
Pharmacology

Background:

High-dose cyclophosphamide (high-CY) is a potent immunosuppressive agent.
Its application is expanding for autoimmune and alloimmune conditions.
Understanding its differential cellular effects is crucial for clinical use.

Purpose of the Study:

To describe the clinical translation of high-dose cyclophosphamide.
To explain the mechanism behind its selective immunosuppression and non-myeloablative effects.

Main Methods:

Investigated the role of aldehyde dehydrogenase expression.
Compared expression levels in hematopoietic stem cells and lymphocytes.
Correlated expression differences with cyclophosphamide sensitivity.

Main Results:

Differential expression of aldehyde dehydrogenase identified between cell types.
This difference explains the selective sensitivity of lymphocytes over stem cells to high-CY.
High-CY demonstrates immunosuppressive effects while preserving hematopoietic stem cells.

Conclusions:

High-dose cyclophosphamide offers a viable therapeutic strategy for autoimmune and alloimmune diseases.
The mechanism of action supports its use as an immunosuppressive, non-myeloablative regimen.
Clinical translation is supported by the understanding of its differential cellular impact.